SuspensionClinical Overview
Deflazacort Oral Suspension 6 mg per 5 ml is an oxazoline derivative of prednisolone with high glucocorticoid and minimal mineralocorticoid activity. In comparative clinical trials, it exhibits a more favorable metabolic and bone safety profile, causing significantly less calcium loss, bone demineralization, growth retardation, and carbohydrate intolerance than conventional prednisone or prednisolone. Indicated for Duchenne muscular dystrophy (DMD) in pediatric patients (age >=2 years), juvenile idiopathic arthritis, severe pediatric asthma, nephrotic syndrome, and chronic autoimmune disorders.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Shake oral suspension bottle vigorously before each administration. Use the provided calibrated oral dosing syringe. Administer orally once daily in the morning with meals or a cup of milk to minimize gastric discomfort. Dose is strictly calculated by pediatric specialist based on body weight (typically 0.9 mg/kg/day for DMD; 0.25 to 1.5 mg/kg/day for other indications). Never discontinue abruptly; taper gradually.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Weight gain, increased appetite, Cushingoid facial appearance (moon face), upper respiratory infections, central obesity, hirsutism, and behavioral changes. Rare/Severe: Osteopenia/vertebral fractures, cataract formation, adrenal insufficiency upon cessation, and severe immunosuppression.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Gradual dosage tapering is mandatory after prolonged courses to prevent acute adrenal crisis. Contraindicated in systemic fungal infections and live virus vaccinations. Periodic monitoring of pediatric linear growth, weight, blood pressure, and ophthalmic status recommended.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Gynecological, Obstetric & Endocrinological Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice or reproductive healthcare guidance. Hormonal medications, uterotonics, corticosteroids, fertility therapies, and emergency contraceptives have profound systemic actions and must be administered strictly under the supervision of a registered gynecologist, obstetrician, or endocrinologist.
Deflazacort Tablets 6 mg
Deflazacort Tablets (6mg) is an oral synthetic oxazoline derivative of prednisolone on the PMBI formulary. It exerts powerful anti-inflammatory and immunosuppressive actions with significantly lower bone mineral resorption, reduced osteoclastogenesis, and lower diabetogenic/weight gain liability compared to conventional prednisone or dexamethasone. Indicated for severe refractory bronchial asthma, allergic disorders, and Duchenne muscular dystrophy.
Deflazacort 30mg + Tamsulosin 0.4mg Tablets
Deflazacort (30mg) and Tamsulosin (0.4mg) Tablets is a specialized medical expulsive therapy (MET) combination. Tamsulosin blocks alpha-1D receptors located predominantly in the lower third of the ureter and ureterovesical junction (UVJ), inhibiting ureteral smooth muscle spasm and dilating the ureteral lumen. Deflazacort is an oxazoline glucocorticoid that exerts potent anti-inflammatory and anti-edematous action around the impacted stone site, reducing localized mucosal swelling and pain. Indicated for medical expulsive therapy of distal ureteral calculi (stones measuring 5 to 10 mm) to accelerate spontaneous stone passage and reduce surgical intervention.